Allen P. Grunes

Mr. Grunes is an antitrust lawyer in Brownstein’s DC office who advises clients on mergers and acquisitions and represents clients before the federal and state antitrust agencies and Congress.  He has experience in a range of industries including media and entertainment, telecommunications, healthcare, and the high-tech sector.  He previously spent more than a decade at the USDOJ Antitrust Division.

Mr. Grunes is co-author of Big Data and Competition Policy (Oxford University Press).  He currently serves on the Advisory Boards of the American Antitrust Institute and the Institute for Consumer Antitrust Studies at Loyola University Chicago School of Law.  He holds a bachelor’s degree from Dartmouth College, a law degree from Rutgers University, and a master of laws degree from New York University.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent
Read More

Universities, Patents, and the Future of U.S. Competitiveness

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties
Read More

How Counterfeit Drugs Threaten U.S. Health and Innovation

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor
Read More